If the promoter of Nrf2 did contain an authentic κB binding site and CML cells did not have genetic aberrance in the Nrf2 pathway, then activation of the NF-κB pathway would enhance Nrf2 mRNA in normal cells. The gene discussed is NFKB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.